A Pancreatic Cancer Drug That Doubled Median Survival Is Now Approved

The FDA approved daraxonrasib for defined groups of adults with metastatic pancreatic adenocarcinoma after a 500-person trial doubled median survival versus chemotherapy. The once-daily RAS inhibitor is not a cure, carries serious risks and has a list price near $39,800 per month. A Pancreatic Cancer Drug That Doubled Median Survival Is Now Approved